Clinical Trial Update: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) [Phase 3]

View source ↗

Summary

Phase 3 trial IsKia TRIAL compares isatuximab plus KRd (Isa-KRd) to KRd alone in newly diagnosed multiple myeloma patients eligible for autologous stem cell tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: European Myeloma Network B.V. | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING